Warren Buffett says Norfolk Southern handled train derailment ‘terribly’

Warren Buffett says Norfolk Southern handled train derailment ‘terribly’


Warren Buffett on Norfolk Southern train derailment response: I think they handled it terribly

Billionaire investor Warren Buffett said Norfolk Southern botched the response to its East Palestine, Ohio train derailment in February, an accident that spilled toxic chemicals into the environment.

“I think they’ve handled it terribly,” the Berkshire Hathaway chairman and CEO said in an interview with CNBC’s Becky Quick from Tokyo on “Squawk Box” on Wednesday.

Buffett, whose BNSF Railway competes with Norfolk Southern, said Norfolk was “tone deaf” for its handling of the Feb. 3 derailment in Ohio.

“I don’t think they’re necessarily bad people for sure, but their response should not have been the same way,” Buffett said. He noted that BNSF had a derailment in March that spilled diesel fuel on tribal land in Washington.

This photo taken with a drone shows the continuing cleanup of portions of a Norfolk Southern freight train that derailed in East Palestine, Ohio, Thursday, Feb. 9, 2023.

Gene J. Puskar | AP

Norfolk Southern did not immediately respond to a request for comment on Buffett’s remarks.

Norfolk Southern CEO Alan Shaw has said the company will support cleanup efforts in Ohio, pledging roughly $24 million in reimbursements and investments. Meanwhile, the National Transportation Safety Board opened a special probe into Norfolk Southern last month that will examine the company’s organization and safety culture.

The Justice Department and the state of Ohio sued Norfolk Southern in March, leading Sens. John Fetterman and Bob Casey of Pennsylvania and Sherrod Brown of Ohio to propose the Railway Accountability Act.

On Tuesday, a truck carrying around 40,000 pounds of contaminated soil from the East Palestine derailment site overturned on a highway.

Buffett’s deputy Greg Abel in the same interview Wednesday said derailments are a “railroad problem” that BNSF and other companies are working to address. He said BNSF aims to improve its practices on safety records and equipment failures to avoid problems at the front end.

Still, Buffett cautioned that rail companies may not be able to eliminate accidents.

“To say that there will never be any more derailments is just plain crazy,” he said.

Buffett added: “We would rather not handle hazardous material. We are a common carrier, we’re required to carry, whether it’s chlorine or you name it.”



Source

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored
Business

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored

In this photo illustration Hantavirus samples are seen in Ankara, Turkiye on May 6, 2026. Arman Onal | Anadolu | Getty Images The U.S. Centers for Disease Control and Prevention said there are no hantavirus cases in the country as of Thursday, as it monitors 41 people for the virus. The agency said the risk […]

Read More
These three artworks could sell for 0 million each next week as May auctions begin
Business

These three artworks could sell for $100 million each next week as May auctions begin

A large-scale Jackson Pollock drip painting titled, “Number 7A, 1948.” Crystal Lau | CNBC A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Nearly $2 billion worth of art will come up […]

Read More
Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data
Business

Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data

A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen plans to advance an experimental drug for Alzheimer’s disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen said its experimental drug that targets tau, a protein associated with the memory-robbing disease, failed to show better responses at higher doses. […]

Read More